1RONCOC, BELLOMOR. New CRRT systems impact on dosedelivery[J]. Am J Kidney Dis, 1997,30 (Suppl 4) : 815- 817.
2BURRY L D, TUNG D D, HALLETT D, et al. Regional cit- rate anticoagulation for PrismaFlex continuous renal replace- ment therapy[J]. Ann Pharmacother, 2009, 43 (9): 1419- 1425.
7DAVIES H, MORGAN D, LESLIE G. A regional citrate an- ticoagulation protocol for predilutional CVVHD[J]. Modified Alabama Protocol Aust Crit Care, 2008 21(3) :154-165.
8GOLPER T A. Continuous arteriovenous hemofiltration in acute renal failure[J]. Am J Kidney Dis, 1985,6:373-386.
9KIERDORF H. Continuous versus intermittent treatment: clinical resultsl results in acute renal failure[J]. Contrib Neph- rol, 1991,93;1-12.
10LAUER A, SACCAGGI A, RONCO C, et al. Continuous ar- terio-venous hemofiltration in the critically ill patient[J]. Ann Int Med, 1983, 99..455-460.
2Furst P 蒋朱明 等.重症患者蛋白质、脂肪和糖的代谢.临床肠外与肠内营养[M].北京:科技文献出版社,2000.153-165.
3TAN H K, UCHINO S, BELLOMO R. The acid-base effects of continuous hemofiltration with lactate or bicarbonate bur fered replacement fluids[J]. Int J Artif Organs, 2003, 26 (6):477-483.
4BARENBROCK M, HAUSBERG M, MATZKIES F, et al. Effects of bicarbonateand lactate-buffered replacement fluids on cardiovascular outcome in CVVH patients[J]. Kidney Int, 2000,58:1751-1757.
5CELIK J B, JOPAL A, KARTAL E, et al. Clinical outcome following the use of inadequte solutions for continuous venovenous hemodiofiltration[J]. Ren Fail, 2008(10):959-964.
6MORITA Y, JOHNSON R W, DORN R E, et al. Regional anticoagulation during hemodialysis using eitrate[J]. Am J Med Sci, 1961,242:32-42.
7KUTSOGIANNIS D J, GIBNEY RTN, STOLLERY D, et al. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients[J]. Kidney Int, 2005,67:2361-2367.
8SCHRIER R W, WANG W, POOLE B, et al. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy[J]. J Clin Invest, 2004,114:5-14.
9CLARK W R, RONCO C. Continuous renal replacement techniques[J]. Contrib Nephrol, 2004,144 : 264-277.
10VIGANO S M, DI FILIPPO S, MANZONI C, et al. Dialysate composition[J]. Contrib Nephrol, 2008,161: 7-11.
5BONE N D, ROGER C. Risk distributions of 519 ICU admission for sepsis according to the definition of SIRS[J]. Chest, 1992,101 (6) : 1481-1483.
6BURRY L D, TUNG D D, HALLETT D, et al. Regional citrate anticoagulation for PrismaFlex continuous renal replacement therapy[J]. Ann Pharmacother, 2009,43(9) : 1419-1425.
7WHEELER A P, BERNARD G R. Treating patients with severe sepsis[J]. N Engl J Med, 1999,340(3):207-214.
8KRAMMER P, WIGGER W, RIEGER J, et al. Arteriovenous hemofiltration: a new and simple method for treatment of over hydrated patients resistant to diuretics[J]. Kiln Wochenschr, 1977,55:1121-1124.
9KOCH T. Origin and mediators involved in sepsis and the systemic inflammatory response syndrome[J]. Kidney Int, 1998, 53(Suppl):66.
10RONCO C, BONELLO M, BORDONI V, et al. Extracorporeal therapies in nonreal disease: treatment of sepsis and the peak concentration hypothesis[J].Blood Purif, 2004,22(1) :164-174.
